Dual Inhibition of Sister Chromatid Separation at Metaphase

Stemmann, Olaf; Zou, Hui; Gerber, Scott A.; Gygi, Steven P.; Kirschner, Marc W.

doi:10.1016/s0092-8674(01)00603-1

Cited by 420 publications

(436 citation statements)

References 46 publications

Supporting

Mentioning

415

Contrasting

Unclassified

Order By: Relevance

“…Figure 7b shows a product ion spectrum for the same concentration of phosphopeptide with a 1.5 s accumulation time in Q2 and a total acquisition time of 2 s. Remarkably, the Q2 CAD MS 2 spectra for this particular peptide exhibited many fragment ions bearing the intact allyl phosphoester and, thus, allowed unambiguous identification of the phosphorylation site. This phenomenon has also been observed for this peptide in a 3-D ion°trap°and°appears°to°be°sequence-specific° [48].…”

Section: Resultssupporting

confidence: 63%

Characterization of a new qQq-FTICR mass spectrometer for post-translational modification analysis and top-down tandem mass spectrometry of whole proteins

Jebanathirajah

Pittman

Thomson³

et al. 2005

J. Am. Soc. Mass Spectrom.

View full text Add to dashboard Cite

The use of a new electrospray qQq Fourier transform ion cyclotron mass spectrometer (qQq-FTICR MS) instrument for biologic applications is described. This qQq-FTICR mass spectrometer was designed for the study of post-translationally modified proteins and for top-down analysis of biologically relevant protein samples. The utility of the instrument for the analysis of phosphorylation, a common and important post-translational modification, was investigated. Phosphorylation was chosen as an example because it is ubiquitous and challenging to analyze. In addition, the use of the instrument for top-down sequencing of proteins was explored since this instrument offers particular advantages to this approach. Top-down sequencing was performed on different proteins, including commercially available proteins and biologically derived samples such as the human E2 ubiquitin conjugating enzyme, UbCH10. A good sequence tag was obtained for the human UbCH10, allowing the unambiguous identification of the protein. The instrument was built with a commercially produced front end: a focusing rf-only quadrupole (Q0), followed by a resolving quadrupole (Q1), and a LINAC quadrupole collision cell (Q2), in combination with an FTICR mass analyzer. It has utility in the analysis of samples found in substoichiometric concentrations, as ions can be isolated in the mass resolving Q1 and accumulated in Q2 before analysis in the ICR cell. The speed and efficacy of the Q2 cooling and fragmentation was demonstrated on an LCMS-compatible time scale, and detection limits for phosphopeptides in the 10 amol/ L range (pM) were demonstrated. The instrument was designed to make several fragmentation methods available, including nozzle-skimmer fragmentation, Q2 collisionally activated dissociation (Q2 CAD), multipole storage assisted dissociation (MSAD), electron capture dissociation (ECD), infrared multiphoton induced dissociation (IRMPD), and sustained off resonance irradiation (SORI) CAD, thus allowing a variety of MS n experiments. A particularly useful aspect of the system was the use of Q1 to isolate ions from complex mixtures with narrow windows of isolation less than 1 m/z. These features enable top-down protein analysis experiments as well structural characterization of minor components of complex mixtures. (J Am Soc Mass Spectrom 2005, 16, 1985

show abstract

Section: Resultssupporting

confidence: 63%

Characterization of a new qQq-FTICR mass spectrometer for post-translational modification analysis and top-down tandem mass spectrometry of whole proteins

Jebanathirajah

Pittman

Thomson³

et al. 2005

J. Am. Soc. Mass Spectrom.

View full text Add to dashboard Cite

show abstract

“…Expression of a nondegradable form of cyclin B1 can lead to an anaphase-like arrest in mammalian cells unable to undergo cytokinesis (Wheatley et al, 1997). However, recent results indicate that a nondegradable form of cyclin B1 may block already the metaphase to anaphase transition in human cells (Chang et al, 2003) and frog eggs (Stemmann et al, 2001). The exact phenotype depends on the amount of nondegradable cyclin B1 expressed in the cell (Stemmann et al, 2001;Hagting et al, 2002;Chang et al, 2003).…”

Section: Proteolysis and Cell Cycle Controlmentioning

confidence: 99%

“…However, recent results indicate that a nondegradable form of cyclin B1 may block already the metaphase to anaphase transition in human cells (Chang et al, 2003) and frog eggs (Stemmann et al, 2001). The exact phenotype depends on the amount of nondegradable cyclin B1 expressed in the cell (Stemmann et al, 2001;Hagting et al, 2002;Chang et al, 2003). Similarly, as in yeast (Wa¨sch and Cross, 2002), more experiments with expression of the nondestructible cyclin B1 (as well as cyclin A2) from the endogenous promoter, mimicking more closely endogenous expression levels and promoter regulation, might clarify the role of cyclin B1 (cyclin A2) destruction in human cells more definitely.…”

Section: Proteolysis and Cell Cycle Controlmentioning

confidence: 99%

Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells

2005

View full text Add to dashboard Cite

“…Furthermore, methods enabling quantitative analysis of proteomes by mass spectrometry have been developed. Among them, two main approaches can be distinguished, namely stable isotope labeling (including ICAT [20], iTRAQ [21], SILAC [22], AQUA [23]) and label-free quantitation (including spectral counting and peak intensity/area quantitation) [24].…”

Section: Current Technologies Enabling Qualitative and Quantitative Amentioning

confidence: 99%

High throughput genomic and proteomic technologies in the fight against infectious diseases

Tanca

Deligios

Addis

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

New technologies have shown significant promise in the fight against infectious diseases, with the discovery of novel molecular targets for in vitro diagnostics and the improved design of vaccines. In developing countries, especially in areas of neglected diseases and resources-poor settings, a number of technological innovations are further needed, such as the integration of old and new biomarkers in suitable analysis platforms, the simplification of existing analysis systems, and the improvement of sample preservation and management. However, in these areas, identification of new biomarkers for infectious diseases is still a core issue in the diagnostic quest. Similarly, new technologies will allow scientists to design vaccines with improved immunogenicity, efficacy and safety in the local area, according to the circulating pathogenic strains and the genetic background of the population to be immunized. In this work we review the current omics-based technologies and their potential for accelerating the development of next generation vaccines and the identification of biomarkers suitable for point-of-care (POC) diagnostic applications.

show abstract

Dual Inhibition of Sister Chromatid Separation at Metaphase

Cited by 420 publications

References 46 publications

Characterization of a new qQq-FTICR mass spectrometer for post-translational modification analysis and top-down tandem mass spectrometry of whole proteins

Characterization of a new qQq-FTICR mass spectrometer for post-translational modification analysis and top-down tandem mass spectrometry of whole proteins

Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells

High throughput genomic and proteomic technologies in the fight against infectious diseases

Contact Info

Product

Resources

About